- Cullinan Oncology press release ( NASDAQ: CGEM ): Q3 GAAP EPS of -$0.54 beats by $0.43 .
- Cash and investments of approximately $607 million as of September 30, 2022
For further details see:
Cullinan Oncology GAAP EPS of -$0.54 beats by $0.43For further details see:
Cullinan Oncology GAAP EPS of -$0.54 beats by $0.43Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Cullinan Oncology Inc. Company Name:
CGEM Stock Symbol:
Market:
2024-06-30 11:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc . (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in patients receiving zipalertinib after prior treatment with amivanta...
2024-05-29 21:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...